NSG 555 Exam 4 Prep Document | 2026/2027 Edition | 200
Verified Questions
NSG 555 Exam 4 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation guide for NSG 555 Exam 4, Nurse Practitioners in Primary Care
II, is meticulously designed for the 2026/2027 academic year. It contains 200 verified questions and
answers that reflect the latest clinical guidelines and best practices. The content is organized to
reinforce key concepts, enhance critical thinking, and ensure readiness for the exam. Each question is
paired with a detailed rationale to support deep understanding and application.
Key Features:
Management of common acute and chronic conditions in primary care
Pharmacological and non-pharmacological treatment strategies
Health promotion and disease prevention across the lifespan
Diagnostic reasoning and evidence-based decision-making
Patient education and culturally competent care
Integration of current clinical practice guidelines
Updates for 2026:
- Updated to align with 2026-2027 clinical practice guidelines
- Revised to include latest pharmacological recommendations
- Enhanced rationales for improved comprehension
- Added new questions reflecting emerging primary care topics
- Reorganized content to mirror exam blueprint
Abstract:
This exam preparation document for NSG 555 Exam 4 is an essential resource for nurse practitioner students
specializing in primary care. It provides a comprehensive review of core competencies required for the
management of patients across the lifespan, with a focus on evidence-based practice. The 200 questions are
carefully selected to cover high-yield topics, including cardiovascular, respiratory, endocrine, and musculoskeletal
disorders, as well as preventive care and health promotion. Each question is accompanied by a detailed answer
and rationale, facilitating active learning and retention. The content is updated to reflect the latest clinical
guidelines and research, ensuring relevance for the 2026/2027 academic year. This guide is designed to enhance
diagnostic reasoning, therapeutic decision-making, and patient-centered care, ultimately preparing students for
successful exam performance and clinical practice.
Keywords:
Primary care, Nurse practitioner, Exam prep, Clinical guidelines, Pharmacology, Diagnostic reasoning, Health
promotion, Chronic disease management
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining the underlying
pathophysiology, clinical reasoning, and evidence-based justification. Distractor options are analyzed to clarify
common misconceptions and reinforce key concepts. The format is designed to mimic the exam style and promote
critical thinking.
Compliance Checklist:
Aligned with 2026-2027 AACN and NONPF competencies
Incorporates latest evidence-based clinical guidelines
Page 1
, Includes rationales for correct and incorrect answers
Covers all major primary care content areas
Suitable for self-assessment and group study
Verified by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Cardiovascular and Hematologic 1-40 Hypertension, Heart Failure, Dyslipidemia, 20%
Conditions Anemia, Anticoagulation
Respiratory and ENT Conditions 41-80 Asthma, COPD, Pneumonia, Allergic 20%
Rhinitis, Pharyngitis
Endocrine and Metabolic 81-120 Diabetes Mellitus, Thyroid Disorders, 20%
Conditions Obesity, Osteoporosis
Musculoskeletal and 121-160 Osteoarthritis, Low Back Pain, Headaches, 20%
Neurological Conditions Peripheral Neuropathy
Preventive Care and Health 161-200 Immunizations, Screening Guidelines, 20%
Promotion Lifestyle Counseling, Geriatric Health
Page 2
,Q1. A patient with type 2 diabetes and CKD stage 3 presents with persistent
albuminuria despite maximal ACE inhibitor therapy. Which combination of agents is
most likely to slow CKD progression and reduce cardiovascular risk?
A. Add SGLT2 inhibitor and titrate ARB to maximally tolerated dose
B. Switch to a direct renin inhibitor and add a thiazide diuretic
C. Add a calcium channel blocker and stop the ACE inhibitor
D. Add a loop diuretic and aldosterone antagonist
Correct Answer: A. Add SGLT2 inhibitor and titrate ARB to maximally tolerated
dose
Rationale: SGLT2 inhibitors reduce albuminuria and slow CKD progression in diabetic
kidney disease, independent of glucose control. Combining an SGLT2 inhibitor with an
ACE/ARB is guideline-recommended. Direct renin inhibitors are not preferred, and
stopping ACE inhibitors is harmful.
Why Wrong:
B - Direct renin inhibitors have no evidence of renoprotection and increase
hyperkalemia risk.
C - Calcium channel blockers do not reduce albuminuria, and stopping ACE inhibitor
worsens proteinuria.
D - Loop diuretics are for volume overload, and aldosterone antagonists increase
hyperkalemia risk with ACE/ARB.
Reference: KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD
Q2. A patient on warfarin for atrial fibrillation presents with an INR of 5.2 and
minor bleeding. What is the most appropriate management?
A. Hold warfarin, give oral vitamin K 2.5 mg, and recheck INR in 24 hours
B. Hold warfarin and give 4-factor prothrombin complex concentrate (PCC)
C. Give fresh frozen plasma and restart warfarin at a lower dose
D. Administer intravenous vitamin K 10 mg and monitor in the hospital
Correct Answer: A. Hold warfarin, give oral vitamin K 2.5 mg, and recheck INR in
24 hours
Rationale: For INR >4.5 with minor bleeding, guidelines recommend holding warfarin
and giving oral vitamin K (2.5 mg) to accelerate INR reduction, with rechecking in 24h.
PCC is for life-threatening bleeding. IV vitamin K 10 mg is for major bleeding or rapid
reversal.
Why Wrong:
B - PCC is reserved for life-threatening bleeding or urgent surgery, not minor
bleeding.
C - FFP is not indicated for non-life-threatening bleeding and may cause volume
overload.
Page 3
, D - High-dose IV vitamin K is excessive and may cause anaphylaxis; it's used for
major bleeding.
Reference: January et al., 2019 AHA/ACC/HRS Atrial Fibrillation Guideline
Q3. Which of the following best distinguishes acute bacterial rhinosinusitis (ABRS)
from viral rhinosinusitis in an adult with persistent symptoms?
A. Symptom duration >10 days with double worsening (new fever, headache, or facial
pain)
B. Presence of purulent nasal discharge and facial pressure
C. Fever >38°C for at least 3 consecutive days
D. Bilateral maxillary tenderness and headache
Correct Answer: A. Symptom duration >10 days with double worsening (new fever,
headache, or facial pain)
Rationale: The AAO-HNS criteria for ABRS include persistent symptoms >10 days, double
worsening (new or worsening fever, headache, or facial pain), or severe onset with fever
>39°C and purulent discharge for 3+ days. Purulent discharge alone is not diagnostic,
and bilateral tenderness is common in viral.
Why Wrong:
B - Purulent discharge and facial pressure are nonspecific and occur in viral
rhinosinusitis.
C - Fever >38°C for 3 days is part of severe onset but must be accompanied by
purulent discharge or double worsening.
D - Bilateral maxillary tenderness is typical of viral rhinosinusitis.
Reference: Rosenfeld et al., 2015 AAO-HNS Clinical Practice Guideline for Acute
Rhinosinusitis
Q4. A patient with major depressive disorder has failed two adequate trials of SSRIs.
Which of the following is the most evidence-based next step?
A. Switch to a different SSRI or SNRI and consider augmentation with bupropion
B. Start a monoamine oxidase inhibitor (MAOI) immediately
C. Add a first-generation antipsychotic such as haloperidol
D. Discontinue pharmacotherapy and refer for electroconvulsive therapy (ECT)
Correct Answer: A. Switch to a different SSRI or SNRI and consider augmentation
with bupropion
Rationale: After two failed SSRI trials, options include switching within class or to SNRI,
or augmenting with bupropion, mirtazapine, or atypical antipsychotics. MAOIs are
later-line due to safety. Haloperidol is not an evidence-based adjunct for depression. ECT
is reserved for severe or treatment-resistant cases with psychosis or catatonia.
Page 4
Verified Questions
NSG 555 Exam 4 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation guide for NSG 555 Exam 4, Nurse Practitioners in Primary Care
II, is meticulously designed for the 2026/2027 academic year. It contains 200 verified questions and
answers that reflect the latest clinical guidelines and best practices. The content is organized to
reinforce key concepts, enhance critical thinking, and ensure readiness for the exam. Each question is
paired with a detailed rationale to support deep understanding and application.
Key Features:
Management of common acute and chronic conditions in primary care
Pharmacological and non-pharmacological treatment strategies
Health promotion and disease prevention across the lifespan
Diagnostic reasoning and evidence-based decision-making
Patient education and culturally competent care
Integration of current clinical practice guidelines
Updates for 2026:
- Updated to align with 2026-2027 clinical practice guidelines
- Revised to include latest pharmacological recommendations
- Enhanced rationales for improved comprehension
- Added new questions reflecting emerging primary care topics
- Reorganized content to mirror exam blueprint
Abstract:
This exam preparation document for NSG 555 Exam 4 is an essential resource for nurse practitioner students
specializing in primary care. It provides a comprehensive review of core competencies required for the
management of patients across the lifespan, with a focus on evidence-based practice. The 200 questions are
carefully selected to cover high-yield topics, including cardiovascular, respiratory, endocrine, and musculoskeletal
disorders, as well as preventive care and health promotion. Each question is accompanied by a detailed answer
and rationale, facilitating active learning and retention. The content is updated to reflect the latest clinical
guidelines and research, ensuring relevance for the 2026/2027 academic year. This guide is designed to enhance
diagnostic reasoning, therapeutic decision-making, and patient-centered care, ultimately preparing students for
successful exam performance and clinical practice.
Keywords:
Primary care, Nurse practitioner, Exam prep, Clinical guidelines, Pharmacology, Diagnostic reasoning, Health
promotion, Chronic disease management
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining the underlying
pathophysiology, clinical reasoning, and evidence-based justification. Distractor options are analyzed to clarify
common misconceptions and reinforce key concepts. The format is designed to mimic the exam style and promote
critical thinking.
Compliance Checklist:
Aligned with 2026-2027 AACN and NONPF competencies
Incorporates latest evidence-based clinical guidelines
Page 1
, Includes rationales for correct and incorrect answers
Covers all major primary care content areas
Suitable for self-assessment and group study
Verified by subject matter experts
Content Area Overview:
Content Area Questions Key Topics Weight
Cardiovascular and Hematologic 1-40 Hypertension, Heart Failure, Dyslipidemia, 20%
Conditions Anemia, Anticoagulation
Respiratory and ENT Conditions 41-80 Asthma, COPD, Pneumonia, Allergic 20%
Rhinitis, Pharyngitis
Endocrine and Metabolic 81-120 Diabetes Mellitus, Thyroid Disorders, 20%
Conditions Obesity, Osteoporosis
Musculoskeletal and 121-160 Osteoarthritis, Low Back Pain, Headaches, 20%
Neurological Conditions Peripheral Neuropathy
Preventive Care and Health 161-200 Immunizations, Screening Guidelines, 20%
Promotion Lifestyle Counseling, Geriatric Health
Page 2
,Q1. A patient with type 2 diabetes and CKD stage 3 presents with persistent
albuminuria despite maximal ACE inhibitor therapy. Which combination of agents is
most likely to slow CKD progression and reduce cardiovascular risk?
A. Add SGLT2 inhibitor and titrate ARB to maximally tolerated dose
B. Switch to a direct renin inhibitor and add a thiazide diuretic
C. Add a calcium channel blocker and stop the ACE inhibitor
D. Add a loop diuretic and aldosterone antagonist
Correct Answer: A. Add SGLT2 inhibitor and titrate ARB to maximally tolerated
dose
Rationale: SGLT2 inhibitors reduce albuminuria and slow CKD progression in diabetic
kidney disease, independent of glucose control. Combining an SGLT2 inhibitor with an
ACE/ARB is guideline-recommended. Direct renin inhibitors are not preferred, and
stopping ACE inhibitors is harmful.
Why Wrong:
B - Direct renin inhibitors have no evidence of renoprotection and increase
hyperkalemia risk.
C - Calcium channel blockers do not reduce albuminuria, and stopping ACE inhibitor
worsens proteinuria.
D - Loop diuretics are for volume overload, and aldosterone antagonists increase
hyperkalemia risk with ACE/ARB.
Reference: KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD
Q2. A patient on warfarin for atrial fibrillation presents with an INR of 5.2 and
minor bleeding. What is the most appropriate management?
A. Hold warfarin, give oral vitamin K 2.5 mg, and recheck INR in 24 hours
B. Hold warfarin and give 4-factor prothrombin complex concentrate (PCC)
C. Give fresh frozen plasma and restart warfarin at a lower dose
D. Administer intravenous vitamin K 10 mg and monitor in the hospital
Correct Answer: A. Hold warfarin, give oral vitamin K 2.5 mg, and recheck INR in
24 hours
Rationale: For INR >4.5 with minor bleeding, guidelines recommend holding warfarin
and giving oral vitamin K (2.5 mg) to accelerate INR reduction, with rechecking in 24h.
PCC is for life-threatening bleeding. IV vitamin K 10 mg is for major bleeding or rapid
reversal.
Why Wrong:
B - PCC is reserved for life-threatening bleeding or urgent surgery, not minor
bleeding.
C - FFP is not indicated for non-life-threatening bleeding and may cause volume
overload.
Page 3
, D - High-dose IV vitamin K is excessive and may cause anaphylaxis; it's used for
major bleeding.
Reference: January et al., 2019 AHA/ACC/HRS Atrial Fibrillation Guideline
Q3. Which of the following best distinguishes acute bacterial rhinosinusitis (ABRS)
from viral rhinosinusitis in an adult with persistent symptoms?
A. Symptom duration >10 days with double worsening (new fever, headache, or facial
pain)
B. Presence of purulent nasal discharge and facial pressure
C. Fever >38°C for at least 3 consecutive days
D. Bilateral maxillary tenderness and headache
Correct Answer: A. Symptom duration >10 days with double worsening (new fever,
headache, or facial pain)
Rationale: The AAO-HNS criteria for ABRS include persistent symptoms >10 days, double
worsening (new or worsening fever, headache, or facial pain), or severe onset with fever
>39°C and purulent discharge for 3+ days. Purulent discharge alone is not diagnostic,
and bilateral tenderness is common in viral.
Why Wrong:
B - Purulent discharge and facial pressure are nonspecific and occur in viral
rhinosinusitis.
C - Fever >38°C for 3 days is part of severe onset but must be accompanied by
purulent discharge or double worsening.
D - Bilateral maxillary tenderness is typical of viral rhinosinusitis.
Reference: Rosenfeld et al., 2015 AAO-HNS Clinical Practice Guideline for Acute
Rhinosinusitis
Q4. A patient with major depressive disorder has failed two adequate trials of SSRIs.
Which of the following is the most evidence-based next step?
A. Switch to a different SSRI or SNRI and consider augmentation with bupropion
B. Start a monoamine oxidase inhibitor (MAOI) immediately
C. Add a first-generation antipsychotic such as haloperidol
D. Discontinue pharmacotherapy and refer for electroconvulsive therapy (ECT)
Correct Answer: A. Switch to a different SSRI or SNRI and consider augmentation
with bupropion
Rationale: After two failed SSRI trials, options include switching within class or to SNRI,
or augmenting with bupropion, mirtazapine, or atypical antipsychotics. MAOIs are
later-line due to safety. Haloperidol is not an evidence-based adjunct for depression. ECT
is reserved for severe or treatment-resistant cases with psychosis or catatonia.
Page 4
